vs
博士伦（BLCO）与Taylor Morrison Home Corp（TMHC）财务数据对比。点击上方公司名可切换其他公司
博士伦的季度营收约是Taylor Morrison Home Corp的1.0倍（$1.4B vs $1.4B），Taylor Morrison Home Corp净利率更高（7.1% vs -4.1%，领先11.2%），博士伦同比增速更快（9.8% vs -26.8%），过去两年博士伦的营收复合增速更高（13.1% vs -16.5%）
博士伦是知名眼健康产品企业，总部位于加拿大安大略省沃恩市，是全球规模最大的隐形眼镜、镜片护理产品、眼科药品、人工晶体及其他眼科手术产品供应商之一。品牌1853年由验光师约翰·鲍什与合伙人亨利·朗姆在美国纽约罗切斯特创立，曾是美国历史最悠久的持续运营企业之一，2013年被整体收购。
泰勒莫里森住房公司是美国规模最大的住宅建筑商之一，总部位于亚利桑那州斯科茨代尔，2007年7月由泰勒伍德罗与莫里森住房合并成立。公司业务覆盖亚利桑那、加利福尼亚、得克萨斯等十余个州，产品涵盖首次置业、中端及中高端住宅，可满足不同层级客户的住房需求。
BLCO vs TMHC — 直观对比
营收规模更大
BLCO
是对方的1.0倍
$1.4B
营收增速更快
BLCO
高出36.6%
-26.8%
净利率更高
TMHC
高出11.2%
-4.1%
两年增速更快
BLCO
近两年复合增速
-16.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.4B | $1.4B |
| 净利润 | $-58.0M | $98.6M |
| 毛利率 | — | 21.0% |
| 营业利润率 | 8.0% | — |
| 净利率 | -4.1% | 7.1% |
| 营收同比 | 9.8% | -26.8% |
| 净利润同比 | -1833.3% | -53.8% |
| 每股收益（稀释后） | $-0.16 | $1.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLCOTMHC
| Q1 26 | — | $1.4B | ||
| Q4 25 | $1.4B | $2.1B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.3B | $2.0B | ||
| Q1 25 | $1.1B | $1.9B | ||
| Q4 24 | $1.3B | $2.4B | ||
| Q3 24 | $1.2B | $2.1B | ||
| Q2 24 | $1.2B | $2.0B |
净利润BLCOTMHC
| Q1 26 | — | $98.6M | ||
| Q4 25 | $-58.0M | $174.0M | ||
| Q3 25 | $-28.0M | $201.4M | ||
| Q2 25 | $-62.0M | $193.6M | ||
| Q1 25 | $-212.0M | $213.5M | ||
| Q4 24 | $-3.0M | $242.5M | ||
| Q3 24 | $4.0M | $251.1M | ||
| Q2 24 | $-151.0M | $199.5M |
毛利率BLCOTMHC
| Q1 26 | — | 21.0% | ||
| Q4 25 | — | 22.0% | ||
| Q3 25 | — | 22.7% | ||
| Q2 25 | — | 23.0% | ||
| Q1 25 | — | 24.4% | ||
| Q4 24 | — | 23.9% | ||
| Q3 24 | — | 25.0% | ||
| Q2 24 | — | 23.7% |
营业利润率BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | — | ||
| Q3 25 | 7.4% | — | ||
| Q2 25 | -0.9% | — | ||
| Q1 25 | -7.3% | — | ||
| Q4 24 | 6.8% | — | ||
| Q3 24 | 3.6% | — | ||
| Q2 24 | 2.1% | — |
净利率BLCOTMHC
| Q1 26 | — | 7.1% | ||
| Q4 25 | -4.1% | 8.3% | ||
| Q3 25 | -2.2% | 9.6% | ||
| Q2 25 | -4.9% | 9.5% | ||
| Q1 25 | -18.6% | 11.3% | ||
| Q4 24 | -0.2% | 10.3% | ||
| Q3 24 | 0.3% | 11.8% | ||
| Q2 24 | -12.4% | 10.0% |
每股收益（稀释后）BLCOTMHC
| Q1 26 | — | $1.12 | ||
| Q4 25 | $-0.16 | $1.77 | ||
| Q3 25 | $-0.08 | $2.01 | ||
| Q2 25 | $-0.18 | $1.92 | ||
| Q1 25 | $-0.60 | $2.07 | ||
| Q4 24 | $-0.00 | $2.29 | ||
| Q3 24 | $0.01 | $2.37 | ||
| Q2 24 | $-0.43 | $1.86 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $383.0M | $652.9M |
| 总债务越低越好 | $5.0B | — |
| 股东权益账面价值 | $6.4B | $6.2B |
| 总资产 | $14.0B | $9.8B |
| 负债/权益比越低杠杆越低 | 0.78× | — |
8季度趋势，按日历期对齐
现金及短期投资BLCOTMHC
| Q1 26 | — | $652.9M | ||
| Q4 25 | $383.0M | $850.0M | ||
| Q3 25 | $310.0M | $370.6M | ||
| Q2 25 | $266.0M | $130.2M | ||
| Q1 25 | $202.0M | $377.8M | ||
| Q4 24 | $305.0M | $487.2M | ||
| Q3 24 | $329.0M | $256.4M | ||
| Q2 24 | $285.0M | $246.8M |
总债务BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | $5.0B | $2.3B | ||
| Q3 25 | $5.0B | $2.2B | ||
| Q2 25 | $5.0B | $2.1B | ||
| Q1 25 | $4.8B | $2.1B | ||
| Q4 24 | $4.8B | $2.1B | ||
| Q3 24 | $4.6B | $2.1B | ||
| Q2 24 | $4.6B | $2.2B |
股东权益BLCOTMHC
| Q1 26 | — | $6.2B | ||
| Q4 25 | $6.4B | $6.3B | ||
| Q3 25 | $6.4B | $6.2B | ||
| Q2 25 | $6.4B | $6.1B | ||
| Q1 25 | $6.4B | $6.0B | ||
| Q4 24 | $6.5B | $5.9B | ||
| Q3 24 | $6.6B | $5.7B | ||
| Q2 24 | $6.5B | $5.5B |
总资产BLCOTMHC
| Q1 26 | — | $9.8B | ||
| Q4 25 | $14.0B | $9.8B | ||
| Q3 25 | $13.8B | $9.6B | ||
| Q2 25 | $13.8B | $9.5B | ||
| Q1 25 | $13.4B | $9.4B | ||
| Q4 24 | $13.5B | $9.3B | ||
| Q3 24 | $13.5B | $9.3B | ||
| Q2 24 | $13.3B | $9.1B |
负债/权益比BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | 0.78× | 0.36× | ||
| Q3 25 | 0.77× | 0.35× | ||
| Q2 25 | 0.77× | 0.35× | ||
| Q1 25 | 0.76× | 0.35× | ||
| Q4 24 | 0.74× | 0.36× | ||
| Q3 24 | 0.70× | 0.37× | ||
| Q2 24 | 0.71× | 0.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $136.0M | — |
| 自由现金流经营现金流 - 资本支出 | $60.0M | — |
| 自由现金流率自由现金流/营收 | 4.3% | — |
| 资本支出强度资本支出/营收 | 5.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-66.0M | — |
8季度趋势，按日历期对齐
经营现金流BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | $136.0M | $646.4M | ||
| Q3 25 | $137.0M | $219.6M | ||
| Q2 25 | $35.0M | $-126.0M | ||
| Q1 25 | $-25.0M | $77.2M | ||
| Q4 24 | $22.0M | $438.2M | ||
| Q3 24 | $154.0M | $135.9M | ||
| Q2 24 | $15.0M | $-233.3M |
自由现金流BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | $60.0M | $635.3M | ||
| Q3 25 | $63.0M | $206.6M | ||
| Q2 25 | $-54.0M | $-133.6M | ||
| Q1 25 | $-135.0M | $68.7M | ||
| Q4 24 | $-70.0M | $428.2M | ||
| Q3 24 | $94.0M | $127.1M | ||
| Q2 24 | $-57.0M | $-241.7M |
自由现金流率BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | 30.3% | ||
| Q3 25 | 4.9% | 9.9% | ||
| Q2 25 | -4.2% | -6.6% | ||
| Q1 25 | -11.9% | 3.6% | ||
| Q4 24 | -5.5% | 18.2% | ||
| Q3 24 | 7.9% | 6.0% | ||
| Q2 24 | -4.7% | -12.1% |
资本支出强度BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 0.5% | ||
| Q3 25 | 5.8% | 0.6% | ||
| Q2 25 | 7.0% | 0.4% | ||
| Q1 25 | 9.7% | 0.4% | ||
| Q4 24 | 7.2% | 0.4% | ||
| Q3 24 | 5.0% | 0.4% | ||
| Q2 24 | 5.9% | 0.4% |
现金转化率BLCOTMHC
| Q1 26 | — | — | ||
| Q4 25 | — | 3.71× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | -0.65× | ||
| Q1 25 | — | 0.36× | ||
| Q4 24 | — | 1.81× | ||
| Q3 24 | 38.50× | 0.54× | ||
| Q2 24 | — | -1.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLCO
| Overthe Counter Products | $489.0M | 35% |
| Pharmaceuticals | $378.0M | 27% |
| Other | $263.0M | 19% |
| Surgical | $249.0M | 18% |
| Brandedand Other Generic Products | $14.0M | 1% |
| Other Revenues | $3.0M | 0% |
| Pharmaceutical Products | $2.0M | 0% |
TMHC
| Home closings revenue, net | $1.3B | 95% |
| Financial services revenue, net | $49.3M | 4% |
| Land closings revenue | $14.5M | 1% |
| Amenity and other revenue | $11.9M | 1% |
